Celltrion set to ramp up pharmacy biz in France with Gifrer acquisition
Celltrion has completed the integration of French health care company Gifrer and plans to strengthen cooperation between the two companies’ sales operations to create greater business synergies, the Korean biopharmaceutical group said Tuesday. According to Celltrion, Chairman Seo Jung-jin visited Gifrer during his trip to France last week and explored ways to combine the French company’s pharmacy…
Celltrion, a Korean biopharmaceutical company, has finalized the integration of French healthcare company Gifrer and aims to enhance collaboration between the two firms' sales operations, the company announced on Tuesday. Celltrion Chairman Seo Jung-jin toured Gifrer during his recent visit to France and examined methods to merge Gifrer's pharmacy sales network with Celltrion's offerings to produce concrete business outcomes.
Founded in 1912, Gifrer is a pharmacy and healthcare enterprise with a sales network encompassing over 9,000 pharmacies and approximately 800 hospitals throughout France. Celltrion acquired complete ownership of Gifrer in May. Despite rapidly expanding its European sales and marketing network by targeting hospitals, medical professionals, and tendering institutions, Celltrion's direct access to pharmacies has remained constrained.
The company considers Gifrer's pharmacy network strategically advantageous as it bridges the gap in Celltrion's direct sales network, enabling prescriptions initiated at hospitals to be connected to dispensations.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
